Search
Now showing items 2301-2310 of 4425
Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.
(OXFORD UNIV PRESS INC, 2022-07-01)
BACKGROUND: Diffuse midline gliomas (DMG) H3K27M-mutant, including diffuse intrinsic pontine glioma (DIPG), are pediatric brain tumors associated with grim prognosis. Although GD2-CAR T-cells demonstrated significant ...
New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer.
(ASSOC DEVELOPPEMENT COMMUNICATION CANCEROLOGIQUE, 2021-11-01)
Since the proof of concept of synthetic lethality between poly(ADP-ribose) polymerase inhibition and loss of BRCA1/2 homologous recombination (HR) function in preclinical models and early phase clinical trials, poly(ADP-ribose) ...
Quantifying evidence toward pathogenicity for rare phenotypes: The case of succinate dehydrogenase genes, SDHB and SDHD.
(ELSEVIER SCIENCE INC, 2022-01-01)
PURPOSE: The weight of the evidence to attach to observation of a novel rare missense variant in SDHB or SDHD in individuals with the rare neuroendocrine tumors, pheochromocytomas and paragangliomas (PCC/PGL), is uncertain. ...
Female leadership in oncology-has progress stalled? Data from the ESMO W4O authorship and monitoring studies.
(ELSEVIER, 2021-12-01)
BACKGROUND: Exploratory research showed that female oncologists are frequently under-represented in leadership roles. European Society for Medical Oncology (ESMO) Women for Oncology (W4O) therefore implemented gender ...
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
(LIPPINCOTT WILLIAMS & WILKINS, 2022-01-20)
PURPOSE: Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine therapy for hormone receptor-positive ...
Combined Peri-operative Lapatinib and Trastuzumab in Early HER2 Positive Breast Cancer can Identify Early Responders: Results from the UK EPHOS-B Trial (CRUK/08/002
(American Association for Cancer Research, 2022-04-01)
The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin.
(NATURE PORTFOLIO, 2022-01-01)
Poly (ADP-ribose) polymerase (PARP) inhibitors elicit antitumour activity in homologous recombination-defective cancers by trapping PARP1 in a chromatin-bound state. How cells process trapped PARP1 remains unclear. Using ...
A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia
(MDPI AG, 2021-10-21)
<jats:p>Acute myeloid leukemia (AML) is a heterogeneous disease with a poor prognosis and remarkable resistance to chemotherapeutic agents. Understanding resistance mechanisms against currently available drugs helps to ...
MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis
(American Society of Hematology, 2022-02-03)
<jats:title>Abstract</jats:title>
<jats:p>The chronic phase of chronic myeloid leukemia (CP-CML) is characterized by the excessive production of maturating myeloid cells. As CML stem/progenitor cells (LSPCs) ...
Structural transitions in the GTP cap visualized by cryo-electron microscopy of catalytically inactive microtubules.
(NATL ACAD SCIENCES, 2022-01-11)
Microtubules (MTs) are polymers of αβ-tubulin heterodimers that stochastically switch between growth and shrinkage phases. This dynamic instability is critically important for MT function. It is believed that GTP hydrolysis ...